Drug intelligence / Profile preview

KD501

Development stage: Unknown
Lead developer: Kwang Dong Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

KD501 is an orally administered drug candidate being developed by Kwang Dong Pharmaceutical for the treatment of Alzheimer's disease and dementia. Originally licensed from the South Korean company Elcomscience, the drug is categorized as a central nervous system therapeutic. While it has been noted in some contexts as having reached Clinical Phase II, official pipeline data from Kwang Dong Pharmaceutical lists it as being in Phase 1 development. Specific details regarding its molecular target or mechanism of action have not been publicly disclosed by the developer.

Targets

Acetylcholinesterase

Beyond the preview

Go deeper on KD501.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KD501.

Explore the full profile